Amdocs Stock Price To Sales

DOX Stock

USD 85.67 0.47 0.55%

Amdocs fundamentals help investors to digest information that contributes to Amdocs' financial success or failures. It also enables traders to predict the movement of Amdocs Stock. The fundamental analysis module provides a way to measure Amdocs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amdocs stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	2.34	3.40

Price To Sales Ratio is likely to rise to 3.40 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Amdocs Company Price To Sales Analysis

Amdocs' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Amdocs Price To Sales

1.97 X

Most of Amdocs' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amdocs is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Amdocs Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Amdocs is extremely important. It helps to project a fair market value of Amdocs Stock properly, considering its historical fundamentals such as Price To Sales. Since Amdocs' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amdocs' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amdocs' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Long Term Debt	Good Will	Intangible Assets	Property Plant Equipment	Short Term Investments	Treasury Stock	Net Tangible Assets	Deferred Long Term Liab	Short Long Term Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.2	0.77	0.05	0.93	0.94	0.81	0.04	0.94	0.53	0.53	0.92	-0.85	0.56	-0.15	-0.86	-0.59	-0.58	-0.58	0.58	0.52	-0.31	0.33
Total Stockholder Equity	0.96		-0.06	0.67	0.28	0.93	0.8	0.89	0.23	0.9	0.38	0.43	0.81	-0.93	0.35	-0.1	-0.82	-0.46	-0.48	-0.46	0.42	0.29	-0.25	0.19
Net Debt	0.2	-0.06		0.6	-0.72	0.13	0.48	-0.28	-0.52	0.26	0.41	0.64	0.45	0.2	0.85	-0.29	-0.37	-0.7	-0.64	-0.63	0.75	0.83	-0.46	0.59
Retained Earnings	0.77	0.67	0.6		-0.19	0.72	0.81	0.49	-0.12	0.85	0.54	0.79	0.81	-0.57	0.88	-0.19	-0.85	-0.81	-0.8	-0.7	0.85	0.75	-0.62	0.67
Accounts Payable	0.05	0.28	-0.72	-0.19		0.14	-0.2	0.4	0.12	0.07	-0.22	-0.19	-0.13	-0.34	-0.52	0.41	0.06	0.33	0.19	0.32	-0.4	-0.58	0.14	-0.27
Net Receivables	0.93	0.93	0.13	0.72	0.14		0.83	0.67	0.23	0.92	0.34	0.62	0.93	-0.82	0.42	-0.31	-0.89	-0.66	-0.67	-0.68	0.61	0.34	-0.49	0.26
Total Liab	0.94	0.8	0.48	0.81	-0.2	0.83		0.64	-0.18	0.89	0.64	0.58	0.93	-0.67	0.75	-0.18	-0.82	-0.67	-0.62	-0.64	0.7	0.73	-0.33	0.46
Total Current Assets	0.81	0.89	-0.28	0.49	0.4	0.67	0.64		0.15	0.72	0.43	0.09	0.52	-0.91	0.22	0.21	-0.55	-0.1	-0.12	-0.06	0.11	0.18	0.07	0.12
Short Term Debt	0.04	0.23	-0.52	-0.12	0.12	0.23	-0.18	0.15		0.05	-0.41	-0.03	0.0	-0.28	-0.44	-0.28	-0.15	0.1	0.02	-0.02	-0.15	-0.46	-0.01	-0.32
Common Stock	0.94	0.9	0.26	0.85	0.07	0.92	0.89	0.72	0.05		0.47	0.62	0.92	-0.78	0.62	-0.16	-0.83	-0.65	-0.67	-0.62	0.74	0.59	-0.48	0.57
Current Deferred Revenue	0.53	0.38	0.41	0.54	-0.22	0.34	0.64	0.43	-0.41	0.47		0.23	0.46	-0.34	0.65	0.34	-0.41	-0.3	-0.24	-0.15	0.33	0.52	-0.06	0.35
Long Term Debt	0.53	0.43	0.64	0.79	-0.19	0.62	0.58	0.09	-0.03	0.62	0.23		0.73	-0.24	0.66	-0.38	-0.8	-0.89	-0.99	-0.86	0.83	0.56	-0.62	0.46
Good Will	0.92	0.81	0.45	0.81	-0.13	0.93	0.93	0.52	0.0	0.92	0.46	0.73		-0.63	0.65	-0.35	-0.89	-0.8	-0.78	-0.79	0.79	0.62	-0.53	0.45
Intangible Assets	-0.85	-0.93	0.2	-0.57	-0.34	-0.82	-0.67	-0.91	-0.28	-0.78	-0.34	-0.24	-0.63		-0.26	-0.03	0.67	0.25	0.28	0.28	-0.25	-0.15	0.18	-0.13
Property Plant Equipment	0.56	0.35	0.85	0.88	-0.52	0.42	0.75	0.22	-0.44	0.62	0.65	0.66	0.65	-0.26		-0.13	-0.61	-0.72	-0.66	-0.6	0.82	0.92	-0.49	0.74
Short Term Investments	-0.15	-0.1	-0.29	-0.19	0.41	-0.31	-0.18	0.21	-0.28	-0.16	0.34	-0.38	-0.35	-0.03	-0.13		0.38	0.62	0.4	0.55	-0.44	-0.18	0.52	-0.02
Treasury Stock	-0.86	-0.82	-0.37	-0.85	0.06	-0.89	-0.82	-0.55	-0.15	-0.83	-0.41	-0.8	-0.89	0.67	-0.61	0.38		0.84	0.82	0.79	-0.69	-0.47	0.53	-0.25
Net Tangible Assets	-0.59	-0.46	-0.7	-0.81	0.33	-0.66	-0.67	-0.1	0.1	-0.65	-0.3	-0.89	-0.8	0.25	-0.72	0.62	0.84		0.91	0.87	-0.87	-0.63	0.73	-0.45
Deferred Long Term Liab	-0.58	-0.48	-0.64	-0.8	0.19	-0.67	-0.62	-0.12	0.02	-0.67	-0.24	-0.99	-0.78	0.28	-0.66	0.4	0.82	0.91		0.89	-0.86	-0.58	0.63	-0.47
Short Long Term Debt	-0.58	-0.46	-0.63	-0.7	0.32	-0.68	-0.64	-0.06	-0.02	-0.62	-0.15	-0.86	-0.79	0.28	-0.6	0.55	0.79	0.87	0.89		-0.83	-0.55	0.63	-0.35
Capital Surpluse	0.58	0.42	0.75	0.85	-0.4	0.61	0.7	0.11	-0.15	0.74	0.33	0.83	0.79	-0.25	0.82	-0.44	-0.69	-0.87	-0.86	-0.83		0.82	-0.73	0.79
Net Invested Capital	0.52	0.29	0.83	0.75	-0.58	0.34	0.73	0.18	-0.46	0.59	0.52	0.56	0.62	-0.15	0.92	-0.18	-0.47	-0.63	-0.58	-0.55	0.82		-0.32	0.79
Net Working Capital	-0.31	-0.25	-0.46	-0.62	0.14	-0.49	-0.33	0.07	-0.01	-0.48	-0.06	-0.62	-0.53	0.18	-0.49	0.52	0.53	0.73	0.63	0.63	-0.73	-0.32		-0.52
Capital Stock	0.33	0.19	0.59	0.67	-0.27	0.26	0.46	0.12	-0.32	0.57	0.35	0.46	0.45	-0.13	0.74	-0.02	-0.25	-0.45	-0.47	-0.35	0.79	0.79	-0.52

Click cells to compare fundamentals

Amdocs Price To Sales Historical Pattern

Today, most investors in Amdocs Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amdocs' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Amdocs price to sales as a starting point in their analysis.

Amdocs Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Amdocs

Price To Sales Ratio Over Time

Amdocs Price To Sales Ratio

Price To Sales Ratio

3.4

At this time, Amdocs' Price To Sales Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Amdocs has a Price To Sales of 1.9684 times. This is 58.73% lower than that of the IT Services sector and significantly higher than that of the Information Technology industry. The price to sales for all United States stocks is 82.76% higher than that of the company.

Amdocs Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amdocs' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amdocs could also be used in its relative valuation, which is a method of valuing Amdocs by comparing valuation metrics of similar companies.

Amdocs is currently under evaluation in price to sales category among its peers.

Amdocs ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amdocs' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amdocs' managers, analysts, and investors.

Environmental

Governance

Social

Amdocs Fundamentals

	Return On Equity	0.14
	Return On Asset	0.0738
	Profit Margin	0.1 %
	Operating Margin	0.15 %
	Current Valuation	10.13 B
	Shares Outstanding	115 M
	Shares Owned By Institutions	98.41 %
	Number Of Shares Shorted	2.86 M
	Price To Earning	19.03 X
	Price To Book	2.85 X
	Price To Sales	1.97 X
	Revenue	4.89 B
	Gross Profit	1.62 B
	EBITDA	855.15 M
	Net Income	542.96 M
	Cash And Equivalents	817.98 M
	Cash Per Share	6.74 X
	Total Debt	807.31 M
	Debt To Equity	0.23 %
	Current Ratio	1.60 X
	Book Value Per Share	30.39 X
	Cash Flow From Operations	822.63 M
	Short Ratio	6.06 X
	Earnings Per Share	4.25 X
	Price To Earnings To Growth	1.12 X
	Target Price	100.29
	Beta	0.75
	Market Capitalization	9.85 B
	Total Asset	6.43 B
	Retained Earnings	6.55 B
	Working Capital	558.25 M
	Current Asset	2.1 B
	Current Liabilities	1.37 B
	Annual Yield	0.02 %
	Five Year Return	1.73 %
	Net Asset	6.43 B
	Last Dividend Paid	1.87

About Amdocs Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Amdocs's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amdocs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amdocs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Amdocs Stock Analysis

When running Amdocs' price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC